Home » Topics » Regulatory » EMA

EMA
RSS

Delcath receives CE mark for Hepatic Chemosat delivery system

April 18, 2011

CHMP recommends new indication for Herceptin in early breast cancer

March 25, 2011

CHMP adopts positive opinion on ViroPharma's Cinryze

March 22, 2011

EMA committee recommends new pediatric indication for Pfizer's Revatio

March 22, 2011

CHMP recommends approval of Eliquis for prevention of venous thromboembolic events

March 22, 2011

CHMP adopts positive opinion regarding new birth control pill NOMAC/E2

March 21, 2011

CHMP adopts negative opinion for Vectibix in combination with chemotherapy

March 21, 2011

CHMP recommends approval of Lucentis in new indication

March 21, 2011

Biovest's BiovaxID receives E.U. orphan drug status in mantle cell lymphoma

March 10, 2011

Pfizer's axitinib receives European orphan drug status in renal cell carcinoma

March 10, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...